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Abstract
Motivated by a clinical trial conducted by Janssen Pharmaceuticals in which a
flexible dosing regimen is compared to placebo, we evaluate how switchers in the
treatment arm (i.e., patients who were switched to the higher dose) would have
fared had they been kept on the low dose. This in order to understand whether
flexible dosing is potentially beneficial for them. Simply comparing these patients’
responses with those of patients who stayed on the low dose is unsatisfactory because
the latter patients are usually in a better health condition. Because the available
information in the considered trial is too scarce to enable a reliable adjustment,
we will instead transport data from a fixed dosing trial that has been conducted
concurrently on the same target, albeit not in an identical patient population. In
particular, we will propose an estimator which relies on an outcome model and a
propensity score model for the association between study and patient characteristics.
The proposed estimator is asymptotically unbiased if at least one of both models
is correctly specified, and efficient (under the model defined by the restrictions on
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the propensity score) when both models are correctly specified. We show that the
proposed method for using results from an external study is generically applicable
in studies where a classical confounding adjustment is not possible due to positivity
violation (e.g., studies where switching takes place in a deterministic manner). Monte
Carlo simulations and application to the motivating study demonstrate adequate
performance.
Keywords: Estimand, Transportability, Causal inference, Double robustness, Positivity
Violation
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1 Introduction
In drug development, it is generally recommended to achieve at least two positive efficacy
trials before applying for health authority approval (U.S. Food and Drug Administration,
1998). Therefore the development program typically consists of multiple phase 3 studies,
which are not necessarily identical or are not necessarily performed in the same population.
In patients with a chronic condition (e.g., Schizophrenia in neurosience), for example, two
of these trials are typically a fixed and flexible dosing trial (e.g., Pollack et al., 1998;
European Medicines Agency, 2004, 2007; Lundbeck, 2018). This is often done in practice
because one can learn different features from these studies; a fixed dosing trial evaluates the
differences in safety, tolerability and efficacy between doses, while a flexible dosing study
more accurately reflects real-life dosing strategies (Lipkovich et al., 2011).
The use of both types of trials appeared for instance in a study program at Janssen
Pharmaceuticals, which motivated this research. This program included a fixed dosing trial
and a flexible dosing trial with protocols that were similar in target patient population (I/E
criteria), primary endpoint and treatment effect measure for the primary endpoint. In the
fixed dosing trial a fixed low dose, a fixed high dose and a (fixed) placebo were compared.
In the flexible dosing trial a (flexible) placebo was compared to a flexible dose, where
patients start with the low dose but are able to switch to the high dose (and vice versa)
depending on the investigator’s decision using a pre-specified deterministic rule based on
efficacy and tolerability. Results from the flexible dosing trial showed that the flexible dose
demonstrated a clinically meaningful and statistically significant improvement in clinical
outcome compared to (flexible) placebo. In the fixed dosing trial, numerically better clinical
outcomes were observed in both dose groups compared to placebo. However, no dose-
response relationship was observed. This raised the question whether flexible dosing is
potentially beneficial for switchers in the treatment arm (i.e., patients who were switched to
the higher dose). This raised the question whether the high dose was potentially beneficial
for a certain subgroup of patients - in particular, whether flexible dosing is potentially
beneficial for switchers in the flexible dosing arm (i.e., patients who were switched to the
higher dose). We therefore aim to estimate the treatment effect in these switchers, which
expresses how different the outcome would have been for them, had they been kept on the
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low dose (i.e. , not switched). Simply comparing these patients’ responses with those of
patients in the flexible dosing arm of the flexible dosing study who stayed on the low dose
is unsatisfactory because these groups are usually not comparable (e.g. , the latter patients
are usually in a better health condition). Additionally, the deterministic rule for switching
complicates a simple adjustment for confounding such as inverse probability weighting due
to positivity violation. Because the available information in the considered trial is too
scarce to enable a relaible adjustment, we will instead use the information contained in the
low dose arm of the fixed dosing trial. Although the fixed and flexible dosing trials have
been conducted concurrently on the same (proposed) treatment, the patient populations
may differ with respect to the distribution of covariates. Because of such differences, it is
also impossible to directly compare the results of the patients in the flexible dosing arm
of the flexible dosing trial to the results of the patients in the low dose arm of the fixed
dosing trial.
In view of this, we will transport data from the low dose arm of the fixed dosing
trial to the flexible dosing trial by using similar statistical techniques as for transporting
inferences from trial participants to new target populations (Zhang et al., 2016; Dahabreh
et al., 2018). We formulate the statistical problem in terms of potential outcomes (Rubin,
1974) and discuss the plausibility of the assumptions required to transport the mean of the
potential outcomes under a given treatment regimen from one trial to another. To avoid
undue reliance on modelling assumptions, we propose a doubly robust estimator. This
estimator relies on an outcome model and a selection (i.e. , propensity score) model for the
association between study and patient characteristics, but only requires at least one of them
to be correctly specified (Robins et al., 1994; Robins and Rotnitzky, 1995; Tsiatis, 2006).
The proposed method for using results from an external study is generically applicable
and creates possibilities in studies where a classical confounding adjustment is not possible
due to positivity violation (e.g,. studies where switching takes place in a deterministic
manner). We moreover assess the finite-sample performance of the method in simulation
studies and support the proposal with an application of the methods to the motivating
study. Lastly, we discuss practical considerations regarding trial designs and problems that
can arise when applying transportability methods.
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2 Setting and Estimation
2.1 Trial Design
The observed data consist of independent and identically distributed observations {(Zi, Yi, Ti, Ri) :
i = 1, . . . , n} on measured baseline covariates Z, outcome Y , a trial indicator T that takes
the value 1 or 0 for subjects assigned to respectively the flexible and fixed dosing trial and
the randomized treatment R which is coded p for patients randomized to placebo, h or l
for patients in the fixed dosing trial randomized to respectively the fixed high and fixed
low dose, and f for patients in the flexible dosing trial randomized to the flexible dose (see
Figure 1). Depending on their response, patients assigned to the flexible dose either stay
on the low dose or switch from the low dose to the high dose (or vice versa). As shown
in Figure 1, the actual assigned treatment will be denoted as A = l for the non-switchers
(S = 0) since they stay assigned to the low dose and A = c for the switchers (S = 1) since
they are assigned to a combination of the low and high dose. For the other patients, we do
not distinguish between the randomized and assigned treatment (A = R).
(FLEXIBLE) PLACEBO (A = p)
FIXED DOSING TRIAL (T = 0)
HIGH DOSE (R = h)
LOW DOSE (R = l)
(FIXED) PLACEBO (R = p)
FLEXIBLE DOSING TRIAL (T = 1)
FLEXIBLE DOSE (R = f)
(FLEX) PLACEBO (R = p) LOW DOSE (A = l)
LOW+HIGH (A = c)
S =
1
S =
0
Figure 1: Trial designs
2.2 Proposal
Let us write Y a to represent the counterfactual outcome under treatment A = a (a ∈
{l, h, c, p}). In particular, Y a is the outcome which would have been seen for given subject
had (s)he been assigned to dose a. To investigate whether flexible dosing is potentially
beneficial (in terms of treatment effect compared to the low dose) for switchers in the
treatment arm of the flexible dosing study, we evaluate how switchers in the treatment
arm would have fared had they been kept on the low dose. In particular, we compare the
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difference in means between the counterfactual outcomes under the flexible dose and the
low dose for switchers in the treatment arm of the flexible dosing study. Since the observed
outcome under the flexible dose for switchers is given by Y c, we can write this difference
in means as
E[Y c − Y l|T = 1, R = f, S = 1]. (1)
Defining Y f as the counterfactual outcome under the flexible dose (not distinguishing
between switchers and non-switchers), this can be rewritten as
E[SY c − SY l|T = 1, R = f ]/P (S = 1|T = 1, R = f)
= E[SY c + (1− S)Y l − SY l − (1− S)Y l|T = 1, R = f ]/
P (S = 1|T = 1, R = f)
= E[Y f − Y l|T = 1, R = f ]/P (S = 1|T = 1, R = f).
by consecutively using the law of iterated expectation, adding and substracting the term
(1− S)Y l and using that SY c + (1− S)Y l = Y f .
The probability P (S = 1|T = 1, R = f) can be simply estimated as the proportion of
switchers in the flexible dosing arm.
The first part of E[Y f − Y l|T = 1, R = f ], θ1 := E[Y f |T = 1, R = f ], can be
directly estimated in the flexible dosing trial. In particular, since the flexible dosing trial
is a randomized trial, an efficient (non-parametric) estimator θˆ1 for θ1 which exploits the
assumption that R |= Z|T = 1 can be obtained in this trial as follows (Tsiatis, 2006; Shu
and Tan, 2018)
1. regress Y on Z among the patients on the flexible dose (R = f) using a canonical
generalized linear working model for the conditional mean of Y : E(Y |R = f, T =
1,Z) = h(Z,η0), where h(Z,η) is a known function, evaluated at a parameter η with
unknown population value η0; e.g. , h(Z,η) = η1 +η
′
2Z for a continuous outcome Y ,
2. and take the average of the predicted values over all patients in the flexible dosing
trial.
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As a result of the simple randomisation in the flexible dosing trial, the estimator θˆ1 has
the appealing feature that misspecification of the outcome model in step 1 does not intro-
duce bias in large samples. Moreover, when the outcome model is correctly specified, this
estimator is asymptotically efficient in the subclass of estimators that are unbiased as soon
as randomisation is independent of baseline covariates Z (Yang and Tsiatis, 2001; Tsiatis,
2006; Moore and van der Laan, 2009; Stallard, 2010).
The mean E[Y l|T = 1, R = f ], denoted as θ2, cannot be estimated directly from the
flexible dosing trial since Y l is not observed for patients in the flexible dosing arm of the
flexible dosing trial. In view of this, we will transport data from the low dose of the
fixed dosing trial to the flexible dosing trial. Sufficient conditions for identifying this mean
by transporting inferences from the fixed dosing trial are mean exchangeability w.r.t. T ,
conditional on Z (transportability) and positivity of trial assignment. The first condition
states that patients with the same characteristics Z in both trials should be comparable in
terms of the outcome Y l that can be expected, i.e., E(Y l|T = 1,Z) = E(Y l|T = 0,Z) =
E(Y l|Z). The second condition states that in each stratum of those baseline covariates Z,
all patients have a positive probability to be assigned to each of the trials. This means that
no patient, based on his/her characteristics Z, is excluded from participating in each ones
of the trials. Under these conditions and using that the flexible dosing trial is randomized,
an estimator θˆ2 for θ2 is obtained by (Zhang et al., 2016; Shu and Tan, 2018; Dahabreh
et al., 2018)
1. fitting a parametric model pi(Z,γ) for the probability of participation in the flexible
dosing trial P (T = 1|X); e.g. , pi(X,γ) = logit−1(γ0 + γ ′1Z),
2. fitting a weighted regression for the conditional mean of Y on Z among the patients
on the low dose of the fixed dosing trial using a canonical generalized linear working
model with weights pˆi(Zi, γˆ)/(1−pˆi(Zi, γˆ)): E(Y |R = l, T = 0,Z) = m(Z,β0), where
m(Z,β) is a known function, evaluated at a parameter β with unknown population
value β0; e.g. , m(Z,β) = β1 + β
′
2Z for a continuous outcome Y ,
3. taking the average of the predicted values over all patients in the flexible dosing trial.
This semi-parametric estimator is consistent when either the model for the selection pi(Z,γ)
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or the outcome m(Z,γ) is correctly specified. Moreover, when both models are correctly
specified, it achieves the non-parametric efficiency bound, under the non-parametric model
where no assumptions are made about the outcome and selection model beyond the trans-
portability and positivity assumptions (Zhang et al., 2016; Shu and Tan, 2018; Dahabreh
et al., 2018).
It follows that Expression (1) can be estimated as (θˆ1 − θˆ2)/pˆiS, with pˆiS the observed
proportion of switchers in the flexible dosing arm. This semi-parametric estimator has the
appealing feature that misspecification of h(Z,η) as well as misspecification of at most
one of the working models used for θˆ2 (i.e. , pi(Z,γ) and m(Z,β)) does not introduce
bias. Moreover, it achieves the non-parametric efficiency bound when all models, h(Z,η),
pi(Z,γ) and m(Z,γ), are correctly specified. In order to calculate the variance of this
estimator, one must take into account that the predictions used to calculate θˆ1 and θˆ2 are
estimated based on particular outcome regression models. It is therefore not sufficient to
compute the sample variance of the mean of these predictions. In Appendix A.3, we show
that this can be easily accommodated.
2.2.1 Remark
Note that the component E[Y f − Y l|T = 1, R = f ] of the treatment effect of interest
(Equation (1)) is an average treatment effect on the “treated” (ATT) because it represents
the mean difference of two potential outcomes over the subpopulation of individuals who
were assigned to the flexible dose. In contrast with estimation of ATE, efficiency can be
gained when the selection model is known since the selection model is not ancillary for
estimation of (components of) ATT (Hahn, 1998). A more efficient estimator for θ1 − θ2
can in particular be obtained by (Shu and Tan, 2018)
1. fitting the same regression models h(Z,η) and m(Z,β), respectively, as before,
2. taking the average of pˆi(Zi, γˆ){hˆ(Zi; ηˆ)− mˆ(Zi; βˆ)}/pˆiT over all patients,
with pˆiT the estimated proportion of patients in the flexible dosing trial. This results
in a semi-parametric estimator for θ1 − θ2 that achieves the semi-parametric efficiency
bound, under the semi-parametric model where the density of T given baseline covariates
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Z is assumed to be known, when the outcome models as well as the selection model
are correctly specified (Shu and Tan, 2018). This variance bound calculated under the
parametric selection model, is no greater than under the less restrictive model where the
selection model is assumed to be unknown. Despite the fact that this estimator is more
efficient, it is generally not unbiased when the selection model is misspecified and therefore
no longer doubly robust. Moreover, as shown in Appendix 6, both estimators for θ are
equivalent when using a logistic regression for pi(Z,γ) with a set of covariates that includes
the covariates used in the models m(Z;β) and h(Z;η).
In the motivating study, the selection model in unknown and we therefore recommend
the doubly robust estimator. In Section 5 we discuss when it would be justified to use this
more efficient estimator.
3 Simulation Study
We conducted a simulation study to compare the finite-sample performance of the proposed
estimators versus a regression estimator (Robins, 1986). The latter estimator is obtained
by estimating θ1 in the same way as before, and estimating θ2 by skipping step one, building
an unweighted regression for Y on Z for the patients in the low dose arm of the fixed dosing
trial in step two and taking the average of the predicted values (based on the unweighted
regression) over all patients in the flexible dosing trial in step three.
3.1 Data Generation
We considered 100 patients in each arm, corresponding with 200 patients in the flexible
dosing trial and 300 patients in the fixed dosing trial. We first generated (independent)
baseline covariates in both trials as Xji ∼ N(0, 1) for j = 1, 2, 3 and Xji ∼ Ber(0.5) for
j = 4, 5, 6; i = 1, . . . , n. To allow for selection into the trials based on baseline covariates,
we then generated two (independent) baseline covariates (j = 7, 8) as Xji ∼ N(0.5, 1) for
patients in the flexible dosing trial and Xji ∼ N(µ, 1) for patients in the fixed dosing trial,
and two (independent) baseline covariates (j = 9, 10) as Xji ∼ Ber(0.6) for patients in the
flexible dosing trial and Xji ∼ Ber(φ) for patients in the fixed dosing trial. The difference
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in the means of these covariate distributions of both trials, which is controlled by φ and µ,
represents selection into the trials based on baseline covariates. To evaluate the strength
of the selection, 5 different combinations for (φ, µ) are considered; Setting 1: (0.6, 0.5),
Setting 2: (0.5, 0.25), Setting 3: (0.4, 0), Setting 4: (0.2, −0.5) and Setting 5: (0.1, −1).
The first setting representing no selection, and the last setting strong selection.
The potential outcomes (Y p, Y l, Y c) are generated as respectively Y p|X ∼ N(mp(X), 1),
Y l|X ∼ N(ml(X), 1) and Y c|X ∼ N(mc(X), 1) with
mp(X) = X3 +X6 +X8 +X10 +X3X6 +X7X9,
ml(X) = X1 +X2 +X3 +X4 +X5 +X6 +X7 +X8 +X9 +X10 +X3X6 +X7X9, and
mc(X) = −X1−0.5X2+X3−X4−0.5X5+X6−0.5X7+X8−0.5X9+X10+X3X6+X7X9.
Moreover, S was generated as S|X ∼ Ber(expit(X3 + X6 + X7 + X8 + X9 + X10)). This
gives us, in all scenarios, a main treatment effect in the switchers of −3.59.
For estimation of the treatment effect, consider an outcome regression model with the
identity link and regressor vectors (1, X1, . . . , X10, X3X6, X7X9)
′ and (1, log |X1|, log |X2|,
log |X3|, X4, X5, X6, log |X7|, log |X8|, X9, X10)′, corresponding to respectively a correctly
specified and misspecfied outcome model. Similarly, consider a selection model with the
logistic link and regressor vectors (1, X7, X8, X9, X10)
′ and (1, log |X7|, log |X8|, X9, X10)′,
corresponding to respectively a correctly specified and misspecfied selection model. We
estimated the performance of each estimator over 5000 runs for each scenario.
3.2 Simulation Results
Table 1 summarizes the simulation results for the different settings under correctly specified
working models, a correctly specified selection model but misspecified outcome models and
correctly specified outcome models but a misspecified selection model.
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When all models are correctly specified, all estimators are approximately unbiased. The
efficient estimator under the non-parametric model has the highest variance. As long as
the selection into both trials is not too strong (Settings 1-3), the efficient estimator under
the semi-parametric model has the lowest variance. This is a consequence of the fact that
the predictions of all patients are used. Interestingly, the regression estimator is the most
efficient in the presence of strong selection (Settings 4 and 5). This because strong selection
and accordingly the extreme weights used in the proposed estimators increase the variance
of these estimators.
When the outcome model is misspecified, the regression estimator is biased. The effi-
cient estimators under non- and semi-parametric models are subject to small sample bias
which disappears for larger samples (See Appendix Table 2). Note that the bias becomes
larger in the presence of stronger selection on covariates. The variance of the two efficient
estimators is comparable.
When the selection model is misspecified, the efficient estimator under the semi-parametric
model is biased since this approach assumes that the selection model is known and thus
correctly specified. The variances are comparable between the different estimators. Note
that the regression estimator is the same as under correctly specified models since it does
not make use of the selection model.
Moreover, the semi-parametric estimator achieving the non-parametric efficiency bound
seems to be most promising in practice. This because comparing the MSEs shows that the
small efficiency gain of the other estimators does not exceed their sensitivity to bias.
Additional simulations were designed to evaluate the performance of the estimators
when the mean exchangeability condition is violated (i.e., when there are unmeasured
common causes of both the outcome and trial selection). For estimation of the treatment
effect, consider an outcome regression model with the identity link and regressor vector
(1, X1, X2, X3, X4, X5, X6, X8, X9, X10, X3X6)
′ and a selection model with the logistic link
and regressor vector (1, X8, X9, X10)
′. Both models are missing the baseline covariate X7
which is a common cause of outcome and trial selection. Moreover, we evaluate the per-
formance of the estimators under violation of mean exchangeability but by assuming that
another baseline covariate X11, which is correlated with X7, is measured. We generated X11
12
(and X7) from a multivariate normal distribution with different covariances/correlations
and mean and variance as described in the previous section. For estimation of treatment
effect, consider an outcome regression model with the identity link and regressor vector
(1, X1, . . . , X6, X8, . . . , X11, X3X6, X11X9)
′ and a selection model with the logistic link and
regressor vectors (1, X11, X8, X9, X10)
′. Simulation results are presented in Appendix Ta-
bles 3 and 4. When the mean exchangeability assumption is violated and there is selection
into the trials, all the estimators are biased. This bias seems to be worse when the selection
is stronger. However, when a baseline covariate X11 is measured that is correlated with the
omitted confounder X7, the bias is less extreme, as expected.
4 Illustration for Motivating Trials
We analyse the data from a study program for a chronic condition at Janssen Pharmaceuti-
cals that motivated this work. For simplicity, we only report analyses restricted to patients
in the full analysis set, on which the efficacy analyses were also performed. In general,
the treatment groups within trials were similar with respect to baseline and demographic
characteristics. The two trials differ in gender, treatment initiated prior to randomization
(to which they had not responded) and demographic characteristics: the majority of sub-
jects were female (70.5% in fixed dosing trial versus 61.9% in flexible dosing trial) and were
initiated with a treatment of category I (57.3% in fixed dosing trial versus 68.2% in flexible
dosing trial), where category of treatment is divided into 2 types- Category I and II (ie,
surgery and chemotherapy in oncology trials). The greatest percentage of subjects was
white (76.6% in fixed dosing trial versus 93.3% in flexible dosing trial) and not Hispanic or
Latino (62.5% in fixed dosing trial versus 92.8% in flexible dosing trial). The subjects in
the fixed dosing study were mainly enrolled in Europe (24.9%) and North America (45.3%),
while the subjects in the flexible dosing study were only enrolled in Europe (60.1%) and
North America (39.9%).
We implemented the method described in Section 2.2 to estimate the treatment effect
in the switchers of the felxible dosing trial, which expresses how different the result would
have been for them, had they been kept on the (fixed) low dose (i.e. , not switched). The
working model h(Z,η), obtained via forward selection at a 15% significance level, for
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the outcome under the flexible dose (A = f) was a linear model with covariates: country,
weight at baseline, age at baseline and the baseline measurement of the outcome. Covariates
were selected on a rather high significance level to guarantee selection of the (important)
predictors of the outcome. After performing backward elimination starting from a model
with all three-way interactions at a 15% significance level, interactions were included for
country and age, for weight and the baseline measurement of the outcome and for weight
and age (See Appendix Table 5). This outcome model is then used for estimating θ1, as
explained in Section 2.2. The working model for the outcome under the fixed low dose
(m(Z,β)) was obtained via forward selection followed by backward elimination starting
from an (unweighted) model with all three-way interactions, both at a 15% significance
level. This resulted in an (unweighted) model with a three-way interaction between the
baseline measurement of the outcome, height at baseline and ethnicity and all lower order
terms (See Appendix Table 6). The working model for the probability of participation
in the flexible dosing trial (pi(Z,γ)), was also obtained via forward selection followed by
backward elimination at a 15% significance level. Hereby, it is important to include outcome
predictors that are also associated with participation to a certain trial, in models for the
outcome and probability in the flexible dosing trial (Brookhart and van der Laan, 2006).
The selection was therefore conducted on the variables selected for the outcome model
m(Z,β) only. This resulted in a selection model only including ethnicity (See Appendix
Table 7). Note that the categories “unknown” and “unreported” are merged to one category
(“unknown”). For estimating θ2, a weighted regression for the outcome under the fixed low
dose is fitted with weights based on the model pi(Z,γ) that is obtained by the selection
procedure for the selection model. The outcome model used in this weighted regression
is the one obtained in the selection procedure for the outcome under the fixed low dose,
where no weights were used. The obtained estimate −4.311 (95% CI: [−9.404, 0.782];
p = 0.096) suggests that on average switching is beneficial compared to staying on the low
dose for switchers of the flexible dosing trial. These results, which are directional but not
significant, are likely influenced by inadequate sample size as the study was not powered
for this (subgroup) analysis.
When conducting this analysis, it was a concern that the transportability and positivity
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of trial assignment assumptions would not be met. This was because both trials were
mainly conducted in different countries, so that both trials differ in patient population
with respect to demographic characteristics as country, race and ethnicity. Fortunately,
these factors were not significantly associated with the outcome under the (fixed) low dose.
As a result, there is some evidence that the difference between countries is relatively less
important and that positivity violation is not a major concern. This may be because
the adjustment for the baseline measurement of the outcome is already explaining the key
differences between countries with respect to the clinical outcome. Moreover, the estimated
probabilities of particpation in the flexible dosing trial were far from one, meaning that
there are no patients with a very low probability to be assigned to the fixed dosing trial.
This is important to exclude near-positivity violations when transporting data from the
fixed dosing trial (fixed low dose) to the flexible dosing trial. The distribution of these
estimated probabilities was similar among patients in the flexible and fixed dosing trial,
reflecting the fairly similar observed covariate distribution in both trials and the absence
of strong selection into the trial (at least based on ethnicity).
To investigate that the findings are not driven by model specification decisions, it is
valuable to conduct a sensitivity analysis. We consider a sequence of different working
models for the outcome model m(Z,β) and the selection model pi(Z,γ), but only consider
the model described in Appendix Table 5 for h(Z,η). The selection model is extended by
allowing the inclusion of variables that are not associated with the outcome. After forward
selection at a 15% significance level, a model including ethnicity, region, treatment initi-
ated prior to randomization and race was obtained. First, a model with interactions was
considered. To prevent violation of the positivity assumption and in view of an inflated
chance of false positives, forward selection to include interactions was performed at a 5%
significance level. This resulted in a selection model with a two-way interaction between
ethnicity and race, and main effects for ethnicity, region, treatment initiated prior to ran-
domization and race. A second model did not include interactions because of the small
amount of individuals in certain (combined) categories. Besides the outcome model under
the low fixed dose that was obtained by combining forward and backward selection (See
Appendix Table 6), we also consider a working model for this outcome via forward selection
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at a 5% significance level for the interactions. This resulted in a model only including the
main effects for the baseline measurement of the outcome, height at baseline and ethnicity.
Moreover, when using the working models for trial selection including variables that were
only associated with trial selection (region, treatment initiated prior to randomization and
race), we also consider the (extended) working models for the outcome that also include
the main effects of these variables.
A summary of the results is shown in Appendix Table 8 and Figure 2. The obtained
estimates are similar in terms of the direction of the effect, but the sensitivity analysis
seems to reinforce the obtained results of the primary analysis. Moreover, given the im-
precision of the estimates, the choice of the models does not impact the size of the effect
and the corresponding confidence intervals too strongly. The imprecision of the estimates
is likely due to lack of overlap in the data with respect to demographic characteristics as
country/region, race and ethnicity.
5 Practical Considerations for Trial Designs
The considered problem raises the question whether the design should be adapted to the
question of interest. For example, a trial with five arms where patients are randomized
to either the low dose, high dose, flexible dosing, fixed placebo or flexible placebo, would
result in a simpler estimator since there would be no need to transport between two studies.
Here, we suggest to use two placebo arms, a flexible and a fixed placebo arm, to make it
better possible to estimate the effect of flexible dosing compared to fixed dosing. Note that
the dose in such a trial would be blinded, but not whether a patient is assigned to a fixed
or a flexible dosing not. This type of design, however, would contradict the demand of the
authorities for two positive efficacy trials. Another preferable possibility may therefore be
to conduct two separate trials, but making them comparable by randomizing patients, in
a simple or stratified way, between the two trials. By randomization, the selection model
is then known and the more efficient estimator proposed in Section 2.2.1 can be used.
However, the feasibility of such a trial need further study.
When using a similar design as the motivating example, which seems most realistic
in practice, it is important to ensure that the patients are properly selected to prevent
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structural violations of the positivity of trial assignment assumption. This is satisfied
when the observed covariate distributions in the fixed and flexible dosing trial are fairly
similar. This can, for example, be done by matching by design; e.g. , for every patient in the
flexible dosing trial, finding a patient with similar observable characteristics to be assigned
to the fixed dosing trial, or vice versa. It may also be that it is not feasible to conduct both
studies in the same countries, resulting in a similar situation of non-overlapping countries
as in the trials which motivated this work. It can then be helpful to randomize countries
itself over the two trials. Meaning that all people from the same country participate in
the same trial, so that one still conduct two separate studies in two contexts, but one can
nevertheless expect a certain comparability.
Independent of the design, it is always a good idea to examine whether the distribution
of the estimated probabilities of being selected for the flexible dosing trial (or fixed dosing
trial) are similar among patients in the flexible dosing trial and patients in the fixed dosing
trial. This would reflect the fairly similar observed covariate distributions in the fixed
dosing trial and flexible dosing trial as well as the absence of strong selection into one of
the trials, at least based on the measured covariates.
6 Discussion
In this paper, we have proposed a method to estimate the treatment effect in the switchers,
which expresses how different the result would have been for them, had they been kept on
the low dose. To realize this, data from a fixed dosing trial that has been conducted concur-
rently on the same target, albeit not in an identical patient population, was transported.
We formulated the statistical problem in terms of potential outcomes and discuss the plau-
sibility of the assumptions required to transport the mean of the potential outcomes under
a given treatment regimen from one trial to another. To avoid undue reliance on modelling
assumptions, we proposed a doubly robust estimator, which relies on an outcome model
and a propensity score model for the association between trial and patient characteristics
but only requires one of them to be correcly specified.
A major challenge in applying the proposed method (and methods to transport data
in general) is the need to collect adequate information on covariates for the mean trans-
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portability assumption to hold. Although the transportability assumption is untestable,
Pearl and Bareinboim have recently proposed methods to facilitate assessing its plausibility
(Bareinboim and Pearl, 2012, 2013; Pearl and Bareinboim, 2014). Moreover, it is impor-
tant to ensure that the patients are properly selected to prevent structural violations of
the positivity of trial assignment assumption. For example, if one of the trials restricted
enrollment to patients under 70 years of age, it is prudent to apply the same restriction in
the other trial.
The fact that the trials in the motivating example were not conducted in the same
countries and/or centers, raised the question whether the transportability and positivity
assumptions were met. This because of investigators in different countries/centers may
handle some situations (e.g. , switching to a different dose) differently, and the possible
differences in demographic characteristics (e.g. , country, race, ethnicity, etc.) and culture
may play an important role in the evaluation of certain outcomes. However, it seemed that
the adjustment for the baseline measurement of the outcome was already explaining the
key differences between countries with respect to the clinical outcome. Moreover, similar
transportability assumptions are made implicitly in meta-analyses, where they are also
considered reasonable, even if the studies were conducted in different studies. Nevertheless,
in practice, one should select the patients in such a way (e.g. , by matching or randomization
over the trials) that the observed covariate distributions are fairly similar and that there
is no strong selection into one of the trials in order to guarantee valid inferences based on
the proposed method.
Simulation results have shown that it is more appropriate to use the proposed method
using doubly robust estimators than using the regression estimator since the double ro-
bustness property gives us two opportunities for correct inference. In adition, the semi-
parametric estimator achieving the non-parametric efficiency bound is more promising in
practice than the one achieving the semi-parametric efficiency bound since the latter is gen-
erally not unbiased when the selection model is misspecified and moreover the efficiency
gain is minor.
Further research is also needed to examine the behavior of the proposed estimators under
model misspecication, as well as to improve their efficiency and stability under misspecifi-
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action of the outcome or selection model (Robins et al., 2008; Cao et al., 2009; Vermeulen
and Vansteelandt, 2015).
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SUPPLEMENTARY MATERIAL
Appendix A: proposed estimator
The focus in this section is on an estimator for E[Y c − Y l|T = 1, R = f, S = 1], or
equivalently E[Y f − Y l|T = 1, R = f ]/P (S = 1|T = 1, R = f), and its properties.
Appendix A.1: Theoretical Derivation of the Estimator
Let n1 and n0, with n = n1 + n0, be the sample sizes in respectively the flexible and fixed
dosing trial. Moreover, n1 = pi
Tn, with piT = P (T = 1).
First, following the reasoning in Tsiatis Tsiatis (2006), it follows that θ1 = E[Y
f |T =
1, R = f ] can be estimated as
θˆ1 = n
−1
1
n1∑
i=1
I(Ri = f)
pˆif
(Yi − h(Zi, ηˆ)) + h(Zi, ηˆ).
By estimating ηˆ as the solution to the equations
∑n
i=1
I(Ai=f)
pˆif
(1,Zi)
′ (Yi − h(Zi;η)) = 0,
it follows that the estimator θˆ1 reduces to n
−1
1
∑n1
i=1 h(Zi, ηˆ); which coincides with the
estimator proposed for θ1 in the main paper.
Next, using the reasoning in Zhang et al. (2016) and Dahabreh et al. (2018), it follows
that θ2 = E[Y
l|T = 1, R = f ] can be estimated as
θˆ2 =
n∑
i=1
[
I(Ti = 0)I(Ri = l)
(1− pi(Zi, γˆ))pˆil pi(Zi, γˆ)
(
Yi −m(Zi; βˆ)
)
+ Tim(Zi; βˆ)
] / n∑
i=1
Ti.
As proven in Zhang et al. (2016) this estimator achieves the non-parametric efficiency
bound. By estimating βˆ as the solution to the equations∑n
i=1
I(Ti=0)I(Ri=l)
(1−pi(Zi,γˆ))pˆil pi(Zi, γˆ)(1,Zi)
′ (Yi −m(Zi;β)) = 0, it follows that the estimator θˆ2 re-
duces to
∑n
i=1
(
Tim(Zi; βˆ)
)
/
∑n
i=1 Ti; which coincides with the estimator proposed for θ2
in the main paper.
Appendix A.2: (Double) Robustness of the Estimator
Because of simple randomisation, pˆif and pˆil are consistent estimator for P (R = f |T = 1)
and P (R = l|T = 0). Additionally, pˆiT is a consistent estimator for P (T = 1). Define the
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probability limits η∗ = plim(ηˆ), β∗ = plim(βˆ) and γ∗ = plim(γˆ), which equal respectively
the true values η0, β0 and γ0 when the working models h(Z,η), m(Z,β) and pi(Z,γ) are
correctly specified, but not necessarily otherwise.
First, by the weak law of large numbers and Slutsky’s theorem, θˆ1 estimates
E
[
TI(R = f)
piTpif
Y +
T
piT
(
1− I(R = f)
pif
)
h(Z,η∗)
]
= E
[
E
{
TI(R = f)
piTpif
Y +
T
piT
(
1− I(R = f)
pif
)
h(Z,η∗)
∣∣∣∣T = 1, R = f,Z}∣∣∣∣T = 1, R = f]
= E [E {Y |T = 1, R = f,Z}|T = 1, R = f ]
= E [Y |T = 1, R = f ] .
We therefore describe the proposed interim estimator as robust, in the sense that it is
consistent even if the outcome model h(Z,η) for E(Y |R = f, T = 1,Z) is misspecified
(Tsiatis, 2008).
Next, we show that θˆ2 has the appealing future that misspecification of at most one of
the two working models does no introduce bias. First, consider the case where pi(Z;γ) is
correctly specified and m(Z;β) (possibly) incorrectly specified:
E
[
I(T = 0)I(R = l)
{1− pi(Z;γ0)} pil pi(Z;γ0) {Y −m(Z;β
∗)}+ T ·m(Z;β∗)
] /
E {T}
= E
[{
T − I(T = 0)I(R = l){1− pi(Z;γ0)} pil pi(Z;γ0)
}
m(Z;β∗) +
I(T = 0)I(R = l)
{1− pi(Z;γ0)} pil pi(Z;γ0)Y
] /
E {T}
= E
[
I(T = 0)I(R = l)
{1− pi(Z;γ0)} pil pi(Z;γ0)Y
] /
E {T}
= E [pi(Z;γ0)E{Y |T = 0, R = l,Z}] /E {T}
= E
[
pi(Z;γ0)E{Y l|T = 1,Z}
]
/E {T}
= E
[
E{TY l|Z}] /E {T}
= E
[
TY l
]
/E {T}
= E
[
Y l|T = 1] .
Second, consider the case where m(Z;β) is correctly specified and pi(X;γ) (possibly)
21
incorrectly specified:
E
[
I(T = 0)I(R = l)
{1− pi(Z;γ∗)} pilpi(Z;γ
∗) {Y −m(Z;β0)}+ T ·m(Z;β0)
] /
E {T}
= E [T ·m(Z;β0)] /E {T}
= E
[
Y l|T = 1] .
Thus, this doubly robust estimator is consistent when either the model for the propensity
score or the expectation of the outcome is correctly specified.
Concludingly, the proposed semi-parametric estimator has the appealing feature that
misspecification of h(Z,η) as well as misspecification of at most one of the working models
used for θˆ2 (i.e. , pi(Z,γ) and m(Z,β)) does not introduce bias. Thus, the proposed
estimator will only be biased if both models used for θˆ2, the model for the selection pi(Z,γ)
and the outcome model m(Z,γ), are misspecified.
Appendix A.3: Asymptotic Variance of the Estimator
Since the asymptotic behavior of an estimator is fully determined by its influence function,
it suffices to focus on the influence function when discussing the estimator’s variance.
Denote the parameter of interest, E[Y c − Y l|T = 1, R = f, S = 1], as θ and its estimator
based on θˆ1 and θˆ2 as θˆ. Define
φ(Y,Z, T, R; θ,η,γ,β, pif , pil, piT , piS) =
1
piT
[
T
{
I(R = f)
pif
(Y − h(Z,η)) + h(Z,η)
}
−
{
I(T = 0)I(R = l)
pil
exp(γTZ)(Y −m(Z;β))
+ Tm(Z;β)
}]/
piS − T
piT
θ.
Under the assumption that ηˆ, γˆ, βˆ, pˆif pˆil, pˆiT and pˆiS are the solutions to respectively the
estimating equations n−1
∑n
i=1Uη(Yi,Zi, Ti, Ri;η) = 0 with Uη(Y,Z, T, R;η) = Z(Y −
ηTZ)TI(R = f)/(piTpif ), n−1
∑n
i=1Uγ(Zi, Ti;γ) = 0 withUγ(Z, T ;γ) = Z{T−expit(γTZ)},
n−1
∑n
i=1Uβ(Yi,Zi, Ti, Ri;β) = 0 with Uβ(Y,Z, T, R;β) = Z(Y − βTZ)I(T = 0)I(R =
l) exp(γTZ)/(pilpiT ), n−1
∑n
i=1Upif (Ti, Ri; pi
f ) = 0 with Upif (T,R; pi
f ) = T (I(R = f)−pif ),
n−1
∑n
i=1Upil(Ti, Ri; pi
l) = 0 withUpil(T,R; pi
l) = I(T = 0)(I(R = l)−pil), n−1∑ni=1UpiT (Ti; piT ) =
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0 with UpiT (T ; pi
T ) = T −piT and n−1∑ni=1UpiS(Ti, Ri, Si; piS) = 0 with UpiS(T,R, S; piS) =
TI(R = f)(S − piS), the influence function of θˆ (Tsiatis, 2006) is given by
φ˜(Y,Z, T, R; θ,η∗,γ∗,β∗, pif , pil, piT , piS) = φ(Y,Z, T, R; θ,η∗,γ∗,β∗, pif , pil, piT , piS)
−E
{
∂φ
∂ηT
(Y,Z, T, R; θ,η∗,γ∗,β∗, pif , pil, piT , piS)
}
E−1
{
∂Uη
∂ηT
(Y,Z, T, R;η∗)
}
Uη(Y,Z, T, R;η
∗)
−E
{
∂φ
∂γT
(Y,Z, T, R; θ,η∗,γ∗,β∗, pif , pil, piT , piS)
}
E−1
{
∂Uγ
∂γT
(Z, T ;γ∗)
}
Uγ(Z, T ;γ
∗)
−E
{
∂φ
∂βT
(Y,Z, T, R; θ,η∗,γ∗,β∗, pif , pil, piT , piS)
}
E−1
{
∂Uβ
∂βT
(Y,Z, T, R;β∗)
}
Uβ(Y,Z, T, R;β
∗)
−E
{
∂φ
∂pif
(Y,Z, T, R; θ,η∗,γ∗,β∗, pif , pil, piT , piS)
}
E−1
{
∂Upif
∂pif
(T,R; pif )
}
Upif (T,R; pi
f )
−E
{
∂φ
∂pil
(Y,Z, T, R; θ,η∗,γ∗,β∗, pif , pil, piT , piS)
}
E−1
{
∂Upil
∂pil
(T,R; pil)
}
Upil(T,R; pi
l)
−E
{
∂φ
∂piT
(Y,Z, T, R; θ,η∗,γ∗,β∗, pif , pil, piT , piS)
}
E−1
{
∂UpiT
∂piT
(T ; piT )
}
UpiT (T ; pi
T )
−E
{
∂φ
∂piS
(Y,Z, T, R; θ,η∗,γ∗,β∗, pif , pil, piT , piS)
}
E−1
{
∂UpiS
∂piS
(T,R, S; piS)
}
UpiS(T,R, S; pi
S)
.
First,
E
{
∂φ
∂ηT
(Y,Z, T, R; θ,η∗,γ∗,β∗, pif , pil, piT , piS)
}
= E
{
1
piS
T
piT
(
1− I(R = f)
pif
)
h′(Z,η∗)
}
= 0T ,
by the fact that pif is guaranteed to be correctly specified under simple randomisation.
Next,
E
{
∂φ
∂γT
(Y,Z, T, R; θ,η∗,γ∗,β∗, pif , pil, piT , piS)
}
= −E
{
1
piS
I(T = 0)I(R = l)
piTpil
exp(γ∗TZ)
{Y −m(Z;β∗)}ZT
}
= 0T ,
and
E
{
∂φ
∂pil
(Y,Z, T, R; θ,η∗,γ∗,β∗, pif , pil, piT , piS)
}
= E
{
1
piS
I(T = 0)I(R = l)
piT (pil)2
exp(γ∗TZ)
{Y −m(Z;β∗)}ZT
}
= 0,
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because of the way β is estimated. Next,
E
{
∂φ
∂pif
(Y,Z, T, R; θ,η∗,γ∗,β∗, pif , pil, piT , piS)
}
= −E
{
1
piS
T
piT
I(R = f)
(pif )2
(Y − h(Z,η∗))
}
= 0,
because of the way η is estimated. Next,
E
{
∂φ
∂piT
(Y,Z, T, R; θ,η,γ,β, pif , pil, piT , piS)
}
= −E
[
1
piS
1
(piT )2
{
T
(
I(R = f)
pif
(Y − h(Z,η)) + h(Z,η)
)
−
(
I(T = 0)I(R = l)
pil
exp(γTZ)(Y −m(Z;β))
+ Tm(Z;β)
)}
− T
(piT )2
θ
]
= −E
[
1
piS
T
(piT )2
{h(Z,η)−m(Z;β)} − T
(piT )2
θ
]
= 0,
because of the way θ is estimated. Finally,
E
{
∂φ
∂βT
(Y,Z, T, R; θ,η,γ,β, pif , pil, piT , piS)
}
= −E
{
1
piS
1
piT
(
I(T = 1)
−I(T = 0)I(R = l)
pil
exp(γ∗TZ)
)
ZT
}
and
E
{
∂φ
∂piS
(Y,Z, T, R; θ,η,γ,β, pif , pil, piT , piS)
}
= − 1
(piS)2
1
piT
E
{
T
(
I(R = f)
pif
(Y − h(Z,η)) + h(Z,η)
)
−
(
I(T = 0)I(R = l)
pil
exp(γTZ)(Y −m(Z;β))
+ Tm(Z;β)
)}
.
Therefore, the influence function of the parameter of interest, θ, reduces to
φ(Y,Z, T, R; θ,η,γ,β, pif , pil, piT , piS)
−E
{
∂φ
∂βT
(Y,Z, T, R; θ,η,γ,β, pif , pil, piT , piS)
}
E−1
{
∂Uβ
∂βT
(Y,Z, T, R;β)
}
Uβ(Y,Z, T, R;β)
−E
{
∂φ
∂piS
(Y,Z, T, R; θ,η,γ,β, pif , pil, piT , piS)
}
E−1
{
∂UpiS
∂piS
(T,R, S; piS)
}
UpiS(T,R, S; pi
S),
with E−1
{
∂Uβ
∂βT
(Y,Z, T, R;β)
}
= E−1
{−I(T = 0)I(R = l) exp(γTZ)/(pilpiT )ZZT} and
E−1
{
∂U
piS
∂piS
(T,R, S; piS)
}
= −E−1{TI(R = f)}. The asymptotic variance of θˆ = (θˆ1 −
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θˆ2)/pˆi
S can then be easily calculated as one over n times the sample variance of
φ(Y,Z, T, R; θˆ, ηˆ, γˆ, βˆ, pˆif , pˆil, pˆiT , pˆiS)
−E
{
∂φ
∂βT
(Y,Z, T, R; θˆ, ηˆ, γˆ, βˆ, pˆif , pˆil, pˆiT , pˆiS)
}
E−1
{
∂Uβ
∂βT
(Y,Z, T, R; βˆ)
}
Uβ(Y,Z, T, R; βˆ)
−E
{
∂φ
∂piS
(Y,Z, T, R; θˆ, ηˆ, γˆ, βˆ, pˆif , pˆil, pˆiT , pˆiS)
}
E−1
{
∂UpiS
∂piS
(T,R, S; pˆiS)
}
UpiS(T,R, S; pˆi
S).
Appendix B: Estimator for Known Selection Model
In this section we focus on the locally semi-parametric efficient estimator, which is more
efficient compared to the proposed estimator but not doubly robust.
Appendix B.1: Theoretical Derivation of the Estimator
Following similar reasonings as in Shu and Tan Shu and Tan (2018), and assuming that
the selection model is known, θ1 can be estimated as
θˆeff1 =
n−1
∑n
i=1
I(Ri=f)Ti
pˆif
(Yi − h(Zi, ηˆ)) + pi(Z; γˆ)h(Zi, ηˆ)
n−1
∑n
i=1 pi(Z; γˆ)
.
Using a logistic selection model for pi(Z;γ), this reduces to
θˆeff
′
1 =
n−1
∑n
i=1
I(Ri=f)Ti
pˆif
(Yi − h(Zi, ηˆ)) + pi(Z; γˆ)h(Zi, ηˆ)
pˆiT
.
By estimating ηˆ as the solution to the equations
∑n
i=1
I(Ri=f)
pˆif
(1,Zi)
′ (Yi − h(Zi;η)), it
follows that the estimator θˆeff
′
1 reduces to n
−1∑n
i=1 pi(Z; γˆ)h(Zi, ηˆ)/pˆi
T ; which coincides
with the semi-parametric efficient estimator proposed for θ1 in the main paper.
A similar reasoning for θ2 yields
θˆeff2 =
n−1
∑n
i=1
I(Ti=0)I(Ri=l)
(1−pi(Zi,γˆ))pˆil pi(Zi, γˆ)
(
Yi −m(Zi; βˆ)
)
+ pi(Zi, γˆ)m(Zi; βˆ)
n−1
∑n
i=1 pi(Z; γˆ)
.
Using a logistic selection model, pi(Z;γ), this reduces to
θˆeff
′
2 =
n−1
∑n
i=1
I(Ti=0)I(Ri=l)
(1−pi(Zi,γˆ))pˆil pi(Zi, γˆ)
(
Yi −m(Zi; βˆ)
)
+ pi(Zi, γˆ)m(Zi; βˆ)
pˆiT
.
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By estimating βˆ as the solution to the equations
∑n
i=1
I(Ti=0)I(Ri=l)
(1−pi(Zi,γˆ))pˆil pi(Zi, γˆ)(1,Zi)
′ (Yi −m(Zi;β)),
it follows that the estimator θˆeff
′
2 reduces to
∑n
i=1
(
pi(Zi, γˆ)m(Zi; βˆ)
)
/pˆiT ; which coincides
with the semi-parametric effictient estimator proposed for θ2 in the main paper.
The variance of these estimators can be obtained by following a similar reasoning as in
Appendix A.3.
Appendix B.2: Remark on the (Double) Robustness of the Esti-
mator
Because of simple randomisation, pˆif and pˆil are consistent estimator for P (R = f |T = 1)
and P (R = l|T = 0). Additionally, pˆiT is a consistent estimator for P (T = 1). Define the
probability limits η∗ = plim(ηˆ), β∗ = plim(βˆ) and γ∗ = plim(γˆ), which equal respectively
the true values η0, β0 and γ0 when the working models h(Z,η), m(Z,β) and pi(Z,γ) are
correctly specified, but not necessarily otherwise.
By the weak law of large numbers and Slutsky’s theorem, θˆeff2 estimates
E
[
I(T = 0)I(R = l)pi(Z;γ∗)
{1− pi(Z;γ∗)} pil {Y −m(Z;β
∗)}+ pi(X;γ∗)m(Z;β∗)
]/
E [pi(Z;γ∗)] . (2)
First, consider the case where the working model for the selection, pi(Z;γ), is correctly
specified and the workig model for the outcome, m(Z;β), possibly incorrectly specified.
Expression (2) then reduces to,
E
[
I(T = 0)I(R = l)pi(Z;γ0)
{1− pi(Z;γ0)} pil {Y −m(Z;β
∗)}+ pi(X;γ0)m(Z;β∗)
]/
E [pi(Z;γ0)]
= E
[(
pi(Z;γ0)− I(T = 0)I(R = l)pi(Z;γ0){1− pi(Z;γ0)} pil
)
m(Z;β∗) +
I(T = 0)I(R = l)pi(Z;γ0)
{1− pi(Z;γ0)} pil Y
]/
E [T ]
= E
[
I(T = 0)I(R = l)pi(Z;γ0)
{1− pi(Z;γ0)} pil Y
]/
E [T ]
= E [pi(Z;γ0)E(Y |T = 0, R = l,Z)]
/
E [T ]
= E
[
pi(Z;γ0)E(Y
l|T = 0,Z)]/E [T ]
= E
[
pi(Z;γ0)E(Y
l|T = 1,Z)]/E [T ]
= E
[
E(TY l|Z)] /E[T ]
= E
[
TY l
]
/E[T ]
= E
[
Y l|T = 1] .
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This estimator, however, has the disadvantage not to be robust against model misspecifi-
cation of pi(Z;γ). To see that, consider the case where the working model for the outcome,
m(Z;β), is correctly specified and the workig model for the propensity score, pi(Z;γ),
possibly incorrectly specified. Expression (2) then reduces to,
E
[
I(T = 0)I(R = l)pi(Z;γ∗)
{1− pi(Z;γ∗)} pil {Y −m(Z;β0)}+ pi(X;γ
∗)m(Z;β0)
]/
E [pi(Z;γ∗)]
= E [pi(Z;γ∗)m(Z;β0)] /E[pi(Z;γ∗)],
where the equation follows from the way β is estimated. This expectation only leads to
E[Y l|T = 1] if the covariates used to estimate m(Z;β) are a subset of the covariates used
to estimate pi(Z;γ). Then, by the estimating equation of a logistic regression with an
intercept E [pi(Z;γ∗)m(Z;β0)] = E [T ·m(Z;β0)] and E[pi(Z;γ∗)] = E[T ]. Moreover,
E [T ·m(Z;β0)] /E[T ] = E [T · E(Y |T = 0, R = l,Z)] /E[T ]
= E
[
T · E(Y l|T = 0,Z)] /E[T ]
= E
[
T · E(Y l|T = 1,Z)] /E[T ]
= E
[
P (T = 1|Z)E(Y l|T = 1,Z)] /E[T ]
= E
[
E(TY l|Z)] /E[T ]
= E
[
TY l
]
/E[T ]
= E
[
Y l|T = 1] .
Consequently, both estimators for θ2 (θˆ2 and θˆ
eff
2 ) are equivalent when using a logistic
regression for pi(Z,γ) with a set of covariates that includes the covariates used in the
model m(Z;β). In that case, θˆeff2 is doubly robust. A similar reasoning for θ1 shows
that both estimators for θ1 (θˆ1 and θˆ
eff
1 ) are equivalent when using a logistic regression for
pi(Z,γ) with a set of covariates that includes the covariates used in the model h(Z;η). To
conclude, both estimators for θ are equivalent when using a logistic regression for pi(Z,γ)
with a set of covariates that includes the covariates used in the models m(Z;β) and h(Z;η).
Appendix C: Tables
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Table 2: Comparison of the bias, the standard error and the mean squared error of the regression
estimator and the estimators proposed in Section 2.2 for a total sample size of 5000, under a misspecified
outcome model.
Non-parametric Semi-parametric Regression
Setting Weights Bias SE MSE Bias SE MSE Bias SE MSE
Setting 1 1.85; 2.11 0 0.023 0.023 −0.001 0.022 0.022 −0.001 0.024 0.024
Setting 2 0.85; 3.80 0.008 0.026 0.026 0.007 0.025 0.025 0.711 0.026 0.531
Setting 3 0.34; 6.13 0.028 0.039 0.040 0.026 0.039 0.039 1.527 0.030 2.360
Setting 4 0.03; 6.63 0.343 0.212 0.330 0.342 0.212 0.329 3.054 0.048 9.377
Setting 5 0.001; 3.36 1.396 0.691 2.638 1.394 0.690 2.633 4.086 0.085 16.777
Note: The column weights shows the 5% and 95% percentiles of the weights pˆi(Zi, γˆ)/(1− pˆi(Zi, γˆ)) among the
patients on the low dose of the fixed dosing trial..
Table 3: Comparison of the bias, the standard error and the mean squared error of the regression estima-
tor and the estimators proposed in Section 2.2 under violation of the mean exchangeability assumption.
Non-parametric Semi-parametric Regression
Setting Weights Bias SE MSE Bias SE MSE Bias SE MSE
Setting 1 1.77; 2.21 −0.001 0.147 0.147 −0.002 0.121 0.121 −0.001 0.147 0.147
Setting 2 1.08; 3.10 0.471 0.164 0.385 0.470 0.137 0.358 0.470 0.159 0.380
Setting 3 0.58; 3.89 0.941 0.212 1.098 0.941 0.188 1.073 0.940 0.186 1.070
Setting 4 0.10; 4.23 1.873 0.592 4.098 1.873 0.566 4.072 1.880 0.321 3.854
Setting 5 0.02; 3.66 2.819 1.585 9.532 2.821 1.559 9.515 2.820 0.584 8.535
Note: The column weights shows the 5% and 95% percentiles of the weights pˆi(Zi, γˆ)/(1− pˆi(Zi, γˆ)) among the
patients on the low dose of the fixed dosing trial..
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Table 5: Regression Results for h(Z,η). Covariates: COUNTRY, country (reference:
Czech Republic); AGE, age at baseline (centered); WEIGHTBL, weight at baseline (cen-
tered); YBL, baseline measurement of the outcome Y (centered).
Dependent variable: Y
Predictors Coefficient (Standard Error)
Constant −24.140(2.076)∗∗∗
COUNTRY
GERMANY 13.690(4.200)∗∗∗
SPAIN −18.292(8.186)∗∗
POLAND 4.219(3.370)
USA 4.476(2.724)
AGE 0.171(0.182)
WEIGHTBL −0.140(0.058)∗∗
YBL −1.147(0.197)∗∗∗
COUNTRY:AGE
GERMANY:AGE 0.222(0.404)
SPAIN:AGE 2.160(0.690)∗∗∗
POLAND:AGE −0.085(0.274)
USA:AGE −0.094(0.222)
WEIGHTBL:YBL 0.013(0.009)
AGE:WEIGHTBL −0.006(0.004)
Observations 112
R2 0.410
Adjusted R2 0.332
Residual Std. Error 11.105 (df = 98)
F Statistic 5.238∗∗∗ (df = 13; 98)
Note: ∗p<0.1; ∗∗p<0.05; ∗∗∗p<0.01
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Table 6: Regression Results for m(Z,β). Covariates: YBL, baseline measurement of
the outcome Y (centered); HEIGHTBL, height at baseline (centered); ETHNIC, ethnicity
(reference: hispanic or latino).
Dependent variable: Y
Predictors Coefficient (Standard Error)
Constant −25.534(2.601)∗∗∗
YBL 0.200(0.563)
HEIGHTBL −0.259(0.230)
ETHNIC
NOT HISPANIC OR LATINO 9.659(3.022)∗∗∗
UNKNOWN 10.625(7.665)
YBL:HEIGHTBL 0.165(0.069)∗∗
YBL:ETHNIC
YBL:NOT HISPANIC OR LATINO −1.372(0.652)∗∗
YBL:UNKNOWN 2.176(1.913)
HEIGHTBL:ETHNIC
HEIGHTBL:NOT HISPANIC OR LATINO 0.032(0.289)
HEIGHTBL:UNKNOWN 0.523(0.915)
YBL:HEIGHTBL:ETHNIC
YBL:HEIGHTBL:NOT HISPANIC OR LATINO −0.200(0.080)∗∗
YBL:HEIGHTBL:UNKNOWN 0.049(0.243)
Observations 115
R2 0.251
Adjusted R2 0.171
Residual Std. Error 12.939 (df = 103)
F Statistic 3.144∗∗∗ (df = 11; 103)
Note: ∗p<0.1; ∗∗p<0.05; ∗∗∗p<0.01
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Table 7: Regression Results for pi(Z,γ). Covariate: ETHNIC, ethnicity.
Dependent variable: T
Predictors Coefficient (Standard Error)
Constant −2.026(0.307)∗∗∗
ETHNIC
NOT HISPANIC OR LATINO 1.942(0.322)∗∗∗
UNKNOWN 0.116(0.618)
Observations 562
Log Likelihood -345.279
Akaike Inf. Crit. 696.558
Note: ∗p<0.1; ∗∗p<0.05; ∗∗∗p<0.01
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